Avicanna (TSX:AVCN) EPS (Diluted) : C$-0.09 (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Avicanna EPS (Diluted)?

Avicanna's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was C$-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.09.

Avicanna's EPS (Basic) for the three months ended in Mar. 2024 was C$-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.09.

Avicanna's EPS without NRI for the three months ended in Mar. 2024 was C$-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.09.

During the past 3 years, the average EPS without NRIGrowth Rate was 46.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 32.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Avicanna's highest 3-Year average EPS without NRI Growth Rate was 46.00% per year. The lowest was -624.30% per year. And the median was 9.90% per year.

Avicanna EPS (Diluted) Historical Data

The historical data trend for Avicanna's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avicanna EPS (Diluted) Chart

Avicanna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-1.16

-1.18

-0.47

-0.25

-0.10

Avicanna Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Diluted)	Get a 7-Day Free Trial															-0.03	-0.02	-0.01	-0.05	-0.01

Competitive Comparison of Avicanna's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Avicanna's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avicanna's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avicanna's PE Ratio distribution charts can be found below:

* The bar in red indicates where Avicanna's PE Ratio falls into.

Avicanna EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Avicanna's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-8.743	-	0)	/	84.708
	=	-0.10

Avicanna's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-1.018	-	0)	/	90.834
	=	-0.01

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.09

Avicanna (TSX:AVCN) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Avicanna EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Avicanna's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Avicanna (TSX:AVCN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (TSX:AVCN) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

AVCNF:USA 0NN:Germany

Address

480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2

Website

https://www.avicanna.com

Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.

Executives

Sheldon Inwentash

10% Security Holder

Avicanna (TSX:AVCN) Headlines

No Headlines